Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.180
-0.280 (-6.28%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Prelude Therapeutics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Prelude Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.00. The average 1-year stock price forecast is 91.39% higher than the current stock price, while the lowest is $6.00 (+43.54%) and the highest is $10 (+139.23%).
Price Target: $8.00 (+91.39%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +91.39% | Jul 15, 2026 |
| D. Boral Capital | D. Boral Capital | Buy Initiates $9 | Buy | Initiates | $9 | +115.31% | May 4, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $3 → $6 | Buy | Maintains | $3 → $6 | +43.54% | Mar 11, 2026 |
Financial Forecast
Revenue This Year
37.92M
from 12.14M
Increased by 212.36%
Revenue Next Year
53.33M
from 37.92M
Increased by 40.65%
EPS This Year
-0.95
from -1.29
EPS Next Year
-0.94
from -0.95
EPS and Forward PE are based on non-GAAP adjusted numbers.